title: Understanding substrate specificity in human and parasite phosphoribosyltransferases through calculation and experiment.
abstract: We present molecular dynamics (MD) simulations on two enzymes: a human hypoxanthine-guanine-phosphoribosyltransferase (HGPRTase) and its analogue in the protozoan parasite Tritrichomonas foetus. The parasite enzyme has an additional ability to process xanthine as a substrate, making it a hypoxanthine-guanine-xanthine phosphoribosyltransferase (HGXPRTase) [Chin, M. S., and Wang, C. C. (1994) Mol. Biochem. Parasitol. 63 (2), 221-229 (1)]. X-ray crystal structures of both enzymes complexed to guanine monoribosyl phosphate (GMP) have been solved, and show only subtle differences in the two active sites [Eads et al. (1994) Cell 78 (2), 325-334 (2); Somoza et al. (1996) Biochemistry 35 (22), 7032-7040 (3)]. Most of the direct contacts with the base region of the substrate are made by the protein backbone, complicating the identification of residues significantly associated with xanthine recognition. Our calculations suggest that the broader specificity of the parasite enzyme is due to a significantly more flexible base-binding region, and rationalize the effect of two mutations, R155E and D163N, that alter substrate specificity [Munagala, N. R., and Wang, C. C. (1998) Biochemistry 37 (47), 16612-16619 (4)]. In addition, our simulations suggested a double mutant (D106E/D163N) that might rescue the D163N mutant. This double mutant was expressed and assayed, and its catalytic activity was confirmed. Our molecular dynamics trajectories were also used with a structure-based design program, Pictorial Representation Of Free Energy Changes (PROFEC), to suggest parasite-selective derivatives of GMP. Our calculations here successfully rationalize the parasite-selectivity of two novel inhibitors derived from the computer-aided design of Somoza et al. (5) and demonstrate the utility of PROFEC in the design of species-selective inhibitors.
authors.affiliation: Graduate Group in Biophysics and Department of Pharmaceutical Chemistry, School of Pharmacy, University of California, San Francisco, San Francisco, California 94143-0446, USA.
authors.forename: J W
authors.initials: JW
authors.lastname: Pitera
authors.forename: N R
authors.initials: NR
authors.lastname: Munagala
authors.forename: C C
authors.initials: CC
authors.lastname: Wang
authors.forename: P A
authors.initials: PA
authors.lastname: Kollman
mesh_terms: D000818:Animals; D003198:Computer Simulation; D006157:Guanosine Monophosphate / Q000737:chemistry; D006801:Humans; D007041:Hypoxanthine Phosphoribosyltransferase / Q000737:chemistry* / Q000235:genetics; D007700:Kinetics; D008958:Models, Molecular; D016297:Mutagenesis, Site-Directed; D010430:Pentosyltransferases / Q000737:chemistry* / Q000235:genetics; D011487:Protein Conformation; D012265:Ribonucleotides / Q000737:chemistry; D012984:Software; D013379:Substrate Specificity / Q000235:genetics; D013816:Thermodynamics; D016835:Tritrichomonas foetus / Q000201:enzymology; D019820:Xanthine
chemical_list: D012265:Ribonucleotides; D019820:Xanthine; C011141:xanthosine monophosphate; D006157:Guanosine Monophosphate; D010430:Pentosyltransferases; C083867:hypoxanthine-guanine-xanthine phosphoribosyltransferase; D007041:Hypoxanthine Phosphoribosyltransferase